Please assess the completion status of the following clinical trial:

Trial Title: Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Cirrhotic patients who were admitted between January 2010 and December 2018.~2. A diagnosis of acute gastrointestinal bleeding.~3. Patients who received terlipressin or somatostatin/octreotide.~4. Age or sex was not limited.~5. Use of endoscopy was not limited.~6. Comorbidity was not limited.~7. Malignancy was not limited.~Exclusion Criteria:~1. Renal parenchymal diseases.~2. Absence of baseline serum creatinine.~3. Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide.~4. Duration of terlipressin or somatostatin/octreotide was less 3 days.~5. Patients who underwent transjugular intrahepatic portosystemic shunt.~6. Patients who underwent surgical shunt, splenectomy with or without devascularization, or liver transplantation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin group (Type: None): Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
- Somatostatin/Octreotide group (Type: None): Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.

Based on this trial design, predict the completion outcome and termination type (if applicable).